Rökavvänjning
Senast uppdaterad: Senast reviderad:
Sakkunnig:Hans Gilljam
- Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
- Socialstyrelsen. Nationella riktlinjer för prevention och behandling vid ohälsosamma levnadsvanor – Stöd för styrning och ledning. 2018 www.socialstyrelsen.se
- Brunnhuber K, Cummings KM, Feit S, Sherman S, Woodcock J. Putting evidence into practice: Smoking cessation. BMJ Publishing Group: 2007.
- Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2016; 3: CD008286. doi:10.1002/14651858.CD008286.pub3 DOI
- Sæterdal I, Ringerike T, Odgaard-Jensen J, Harboe I, Hagen G, Reikvam A, Klemp M. Legemidler til røykeslutt. Rapport fra Kunnskapssenteret nr 08, 2010.
- Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 135-44. Canadian Medical Association Journal
- Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;5:CD000146. doi: 10.1002/14651858.CD000146.pub5. DOI
- Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 25 weeks. A randomized clinical trial. JAMA 2016; 315: 371-9. doi:10.1001/jama.2015.19284 DOI
- Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: a systematic review and meta-analysis. BMJ 2009; 338: b1024. BMJ (DOI)
- Berlin I, Grangé G, Jacob N, Tanguy M-L. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014; 348: g1622. BMJ (DOI)
- Oncken C, Dornelas E, Green J, et al. Nicotine gum for pregnant smokers: A randomized controlled trial. Obstet Gynekol 2008; 112: 859-67. PubMed
- Ivan Berlin, Gilles Grangé, Nelly Jacob, Marie-Laure Tanguy. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014; 348. doi: 10.1136/bmj.g1622. (Published 11 March 2014)
- Piper ME, Fiore MC, Smith SS et al. Identifying effective intervention components for smoking cessation: a factorial screening experiment. Addiction. 2016 Jan;111(1):129-41. PMID: 26582269 PubMed
- Anthenelli RM, Benowitz NL, West R et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387: 2507-20. pmid:27116918 PubMed
- Thomas KH, Martin RM, Davies NM, et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practicee Research Datalink: prospective cohort study. BMJ 2013; 347: f5704. BMJ (DOI)
- Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2011; 2: CD006103. Cochrane (DOI)
- Koegelenberg CFN, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation. JAMA 2014; 312: 155-161. Journal of the American Medical Association
- Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder. JAMA 2014; 311: 145-54. doi:10.1001/jama.2013.285113. PMID: 24399553 PubMed
- Gunnel D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805. BMJ (DOI)
- Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350: h1109. doi:http://dx.doi.org/10.1136/bmj.h1109
- FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease.
- Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856. BMJ (DOI)
- Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking. Arch Intern Med 2011; 171: 770-7. PubMed
- West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-200. New England Journal of Medicine
- Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; 1: CD000031. pmid:24402784 PubMed
- White AR, Rampes H, Ernst. Acupuncture for smoking cessation. Cochrane Database Syst Rev 2002; (2): CD000009. Cochrane (DOI)
- Hartmann-Boyce J, Lancaster T, Stead LF. Print-based self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2014 Jun 3;6:CD001118. DOI: 10.1002/14651858.CD001118.pub3. DOI
- Hans Gilljam, seniorprofessor och läkare, Institutionen för folkhälsovetenskap, Karolinska institutet
- Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet